CHIMERIX INC
CMRX evidence brief
What we can confirm
- BioSniper Score:
- 7.1 / 10
- Lead Asset:
- dordaviprone (BLA Filed)
What it means
What to watch
Prepared research question
What matters most for CMRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
dordaviprone (BLA Filed)
Next Catalyst
—
Tracking 2 pipeline candidates · 1 FDA decision for CHIMERIX INC.
Run CHIMERIX INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CHIMERIX INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: BLA Filed
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is CHIMERIX INC's lead drug candidate?
CHIMERIX INC's most advanced tracked candidate is dordaviprone (BLA Filed) for recurrent H3 K27M-mutant diffuse glioma.
Who is the CEO of CHIMERIX INC?
North Carolina April is the chief executive officer of CHIMERIX INC (CMRX).
What therapeutic areas does CHIMERIX INC focus on?
CHIMERIX INC develops therapies across Oncology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.